News

Phase Genomics Welcomes David Shoultz as Chief Business Officer

Phase Genomics Welcomes David Shoultz as Chief Business Officer

Phase Genomics Welcomes David Shoultz as Chief Business Officer

SEATTLE--Phase Genomics, Inc., a leading innovator at the forefront of genomics technology development, has recently announced a significant addition to their executive team. David Shoultz, PhD, MBA, has been appointed as the company’s first Chief Business Officer. His appointment aims to drive growth, enhance market awareness, and amplify the impact of technological advancements in the realm of human health.

Strategic Importance of New Leadership

“David’s experience in leading diverse organizations across various therapeutic areas and global public health is crucial for our growth strategy,” stated Ivan Liachko, PhD, founder and CEO of Phase Genomics. His extensive background in the industry brings the needed expertise at a pivotal time when the company is focusing on accelerating the adoption of its technologies, poised to unlock and integrate new layers of scientific discovery. We are thrilled to welcome David to our team as we reinforce our mission to improve health outcomes worldwide.

David Shoultz's Background

David Shoultz has enjoyed a noteworthy career, including aiding in the launch of Monod Bio, an Institute for Protein Design (IPD) spin-out where he served as co-founder and COO. His previous roles include being a vital member of the global health product development team at the Bill & Melinda Gates Foundation, directing the global drug development program at PATH, and holding scientific leadership positions in various companies such as Neoleukin Therapeutics and PPD. Throughout his career, Shoultz has successfully raised over $150 million in venture capital and non-dilutive funding to support pioneering innovations in health and medicine.

Excitement for the Future

“Phase Genomics has been built on a dedicated and contagious scientific curiosity, which is one of the primary reasons I am proud to join this team on the cutting edge of discovery,” remarked David Shoultz. He acknowledged the company's impressive track record of technological breakthroughs over nearly a decade, signaling that even more advancements are on the horizon. Shoultz emphasized the commitment of Phase Genomics to not only advance leading-edge genomic tools for research but to demonstrate their real-world impact. Together, the team is set to seize significant opportunities that extend beyond laboratory settings, particularly in pressing therapeutic areas like oncology and infectious diseases.

Current Academic Roles

Besides his responsibilities at Phase Genomics, Shoultz holds an affiliate professorship in the Department of Epidemiology at the University of Washington. He serves as a translational advisor within the University’s IPD, showcasing his broader commitment to education and innovation in the field of genomics.

Anticipation of Upcoming Engagements

Shoultz is scheduled to attend the BIO Investor Forum in mid-October, where he will represent Phase Genomics in San Francisco. This engagement illustrates the company’s commitment to fostering connections that will lead to the further development of its groundbreaking technologies.

About Phase Genomics

Phase Genomics utilizes proprietary ultra-long-range genome sequencing technology to facilitate genome assembly and microbiome discovery, in addition to analyzing genomic integrity and chromosomal abnormalities. Their extensive portfolio includes laboratory and computational services, reagent kits, and genomic services, featuring top-tier genome and metagenome assembly software.

Founded in 2015 in Seattle by a dedicated group of genome scientists and software engineers, the company is on a mission to equip researchers with genomic tools that drive transformative discoveries.

Frequently Asked Questions

1. Who is David Shoultz?

David Shoultz is the newly appointed Chief Business Officer of Phase Genomics, bringing extensive experience in global public health and biotechnology.

2. What does Phase Genomics do?

Phase Genomics specializes in genome sequencing technology, enabling significant advancements in genomic research and healthcare.

3. Why is Shoultz’s appointment significant?

Shoultz’s diverse experience is expected to accelerate Phase Genomics’ growth and enhance its technological adoption in healthcare.

4. What type of technologies does Phase Genomics focus on?

Phase Genomics focuses on ultra-long-range genome sequencing as well as tools for microbiome discovery and genomic integrity analysis.

5. What is the vision of Phase Genomics?

The company aims to empower scientists with advanced genomic tools that lead to groundbreaking discoveries, improving health globally.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 173

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Nellie's 50% Booking Jump Reveals a Quieter Luxury

Updated Category News Views 50

Silicon Valley’s rich are apparently tired of performing wealth for strangers, and frankly, that tracks. Nellie’s 2027 forecast says its mostly tech-money clientele is moving past the old trophy case of private jets, famous resort towns, and suites priced like small houses. The prize now is privacy, a clean schedule, and somebody competent fixing the ugly little...

Continue Reading
Villa Group’s Punta Mita Bet Adds 305 Luxury Resort Keys

Updated Category News Views 74

A 12.6-acre slice of Riviera Nayarit coastline is about to get a very expensive makeover, assuming The Villa Group can turn a handsome plan into a functioning resort without the usual development headaches. The company says it has acquired a beachfront parcel in Litibú and intends to build Villa La Valencia Punta Mita, a 305-accommodation luxury property aimed squarely...

Continue Reading
Esquire Spotlight Puts Trauma Cleanup Work in Focus

Updated Category News Views 21

A national magazine profile is an odd milestone for a business built around other people’s worst days. David Lesaffre, co-owner and operator of T.A.C.T. 48, T.A.C.T. AZ, and T.A.C.T. Fort Worth, has been featured by Esquire in a piece called “The Trauma Cleaners.” The attention is deserved, frankly, because biohazard remediation is one of those necessary services...

Continue Reading
TGHL Eyes U.S. Battery Shift Through EnChem Merger

Updated Category News Views 43

A Policy Squeeze Is Rewriting the Battery Map Battery supply chains are getting shoved through a narrower gate, and that is exactly why this proposed deal deserves a hard look. The GrowHub Limited wants to acquire EnChem America, a Georgia-based lithium-ion battery electrolyte producer, and the timing is plainly built around Washington's push to reduce reliance on...

Continue Reading
Knotch Bets Brands Need Answers, Not More Web Pages

Updated Category News Views 229

Pages are starting to look like expensive filing cabinets A website that cannot answer an agent may soon be expensive wallpaper. That is the blunt premise behind Knotch's Ace for Agents, launched Nov. 17, 2026, and frankly it lands because plenty of big companies have spent years piling pages atop pages until nobody can tell which claim is current. Knotch is pitching an...

Continue Reading
Lotte's Songdo Plant 1 Puts 120,000 Liters on Deck

Updated Category News Views 44

A 120,000-liter biomanufacturing plant is not a ribbon-cutting trinket; it is a serious industrial bet that has to earn its keep one qualified batch at a time. LOTTE Biologics has completed Plant 1 at its Songdo Bio Campus in Incheon, South Korea, giving the company a sizable new production base as it tries to become a more consequential player in the global CDMO...

Continue Reading
NextPatient’s KLAS Marks Signal Specialty Workflow Fit

Updated Category News Views 35

A 93.3 score in healthcare software deserves a second look. Not a victory lap, not a drumroll—just a serious look at whether the product is solving an annoying, expensive operational problem for specialty practices. NextPatient’s recognition in the 2026 KLAS Emerging Solutions Top 20 Report lands in that category. The company placed in the top five for improving...

Continue Reading
Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 105

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading
Seeking Alpha Premium Review: Data Meets Human Judgment

Updated Category News Views 102

A spreadsheet can spot a cracked windshield, but it cannot tell you where the truck is headed. That is the useful, slightly irritating truth behind Seeking Alpha Premium’s 2026 pitch: it puts an enormous amount of stock-research machinery in one place, yet the investor still has to do the driving. Software Experts has highlighted the service in its review of...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Crypto Volatility and the REX Osprey XRP ETF

Updated Category News Views 134

Cryptocurrency Market Overview and Recent Trends Up until October, the cryptocurrency market was experiencing significant growth, with a total capitalization reaching approximately $4.28 trillion. This surge was driven by abundant liquidity and a heightened risk appetite among investors. However, the capital markets can be unpredictable, leading to a swift and adverse...

Continue Reading
Intelligent Bio Inks Global Deal to Expand Drug Testing Solutions

Updated Category News Views 126

Intelligent Bio Solutions Launches Global Distribution Pact Intelligent Bio Solutions Inc. (NASDAQ: INBS) has recently announced an exciting global distribution partnership with SMARTOX. This collaboration aims to introduce their innovative SmarTest Patch, a cutting-edge product designed for drug detection, to international markets beyond the U.S. and Canada, marking a...

Continue Reading
Discover the Long-Term Growth of American Financial Group AFG Stock

Updated Category News Views 148

The Remarkable Journey of American Financial Group (AFG) American Financial Group (AFG) has significantly outperformed the market over the past twenty years, showing an annualized return of 9.37%, which surpasses the market by 1.29%. With a market capitalization standing at an impressive $10.39 billion, AFG is a noteworthy player in the financial sector. Investment...

Continue Reading
Current Sentiment Analysis: Canaan Inc's Short Interest Insights

Updated Category News Views 352

Canaan Inc's Current Short Interest Overview Canaan Inc (NYSE: CAN) is witnessing changes in its stock sentiment, particularly regarding its short interest. Recent reports indicate that the short interest, expressed as a percentage of the float, has dropped by 8.14%. Currently, 36.17 million shares are sold short, representing 8.58% of the total shares available for...

Continue Reading
CalExitNow Push for CA GOP Ban & Sovereignty Talks

Updated Category News Views 296

California's Political Pot Stirs In the wild world of politics, California stands as a fiery beacon yet again. This time, CalExitNow, a fiery group championing California's self-determination, is taking aim at the state’s Republican Party. Reminds me of a stock under pressure—hesitate at your peril as the winds of change sweep through. Disqualification Petition: A...

Continue Reading